14.03 HYPROMELLOSE
Eye drops, 3 mg per mL, 10 mL,
In a Wink Moisturising®; Genteal®,
Alcon Laboratories (Australia) Pty Ltd

# Purpose of Item

* 1. To request a change to the bottle volume of the In a Wink Moisturising® and Genteal® brands of hypromellose from 15 mL to 10 mL.

# Requested listing

* 1. The sponsor originally requested listing at the same price as the current 15 mL bottle and claimed there would be no additional cost to the PBS as 5 mL is regularly wasted due to the short shelf life of hypromellose, however did not provide any evidence to support this claim. No other changes to the listing were requested.
	2. In further discussions with the sponsor, the Department requested the sponsor either (a) offer a price commensurate with the reduced volume in the 10 mL bottle, or (b) make a minor submission to the PBAC with evidence to support the argument the smaller pack size would not result in an additional cost to the PBS. The sponsor elected to provide a commensurate price offer.
	3. The submission requested a new approved ex-manufacturer price (AEMP) of $2.08; a reduction of ~33% for both brands, however noted a brand premium of $4.34 applies to the Genteal brand, and requested this continue to apply. The requested listing is presented below.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name, Restriction,****Manner of administration and form** | **Max.****Qty (Packs)** | **Max.** **Qty (Units)** | **No. of****Rpts** | **Proprietary Name and Manufacturer** |
| HYPROMELLOSEeye drops 3 mg per mL, 10 mL | 11 | 11 | 55 | In a Wink MoistuirisingGenteal | Alcon Laboratories (Australia) Pty Ltd |
| **Category /** **Program** | GENERAL – General Schedule (Code GE) |
| **Prescriber type:** | [ ] Dental [x] Medical Practitioners [x] Nurse practitioners [x] Optometrists[ ] Midwives |
| **PBS Indication:** | Severe dry eye syndrome, including Sjogren's syndrome |

# Pricing considerations

* 1. As noted above, the Secretariat consulted with the sponsor to obtain a price offer commensurate with the smaller pack size.

# PBAC Outcome

* 1. The PBAC agreed with the change to the pack size, and noted that the change to be processed by the Secretariat and noted the price reduction offered by the sponsor maintained price parity on a per mL basis.

# Recommended listing

* 1. Amend item as follows:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name, Restriction,****Manner of administration and form** | **Max.****Qty (Packs)** | **Max.** **Qty (Units)** | **No. of****Rpts** | **Proprietary Name and Manufacturer** |
| HYPROMELLOSEeye drops 3 mg per mL, 10 mL | 11 | 11 | 55 | In a Wink MoistuirisingGenteal | Alcon Laboratories (Australia) Pty Ltd |
| **Category /** **Program** | GENERAL – General Schedule (Code GE) |
| **Prescriber type:** | [ ] Dental [x] Medical Practitioners [x] Nurse practitioners [x] Optometrists[ ] Midwives |
| **PBS Indication:** | Severe dry eye syndrome, including Sjogren's syndrome |

# Context for Decision

The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

# Sponsor’s Comment

The sponsor had no comment.